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Introduction  and  objective:  Anemia  is a  common  comorbidity  in patients  with  acute  coro-
nary syndromes  (ACS),  and  is associated  with  higher  risk  for  both  bleeding  and ischemic
complications.  We  aimed  to  assess  the  predictive  ability  of  bleeding  risk  scores  (Can  Rapid
risk stratification  of  Unstable  angina  patients  Suppress  ADverse  outcomes  with  Early  imple-
mentation  of  the ACC/AHA  guidelines  [CRUSADE],  Mehran  and  Acute  Coronary  Treatment  and
Intervention  Outcomes  Network  [ACTION])  in ACS  patients  with  anemia.
Methods:  All  consecutive  ACS  patients  were  prospectively  included.  The  primary  outcome  was
in-hospital  major  bleeding  according  to  the  CRUSADE,  Mehran  and ACTION  definitions.  Anemia
was defined  as hemoglobin  <130  g/l  in men  and  <120  g/l  in  women.  The  predictive  ability  of  the
bleeding risk  scores  was  assessed  by  binary  logistic  regression,  calculating  receiver  operating
characteristic  (ROC)  curves  and  their  corresponding  area  under  the  curve  (AUC).
Results: We  included  2255  patients,  mean  age  62.4  years.  Anemia  was  present  in  550  patients
(24.4%). Patients  with  anemia  had  a  significantly  higher  prevalence  of  comorbidities.  The  three
bleeding risk  scores  adequately  predicted  major  bleeding  in  the  whole  cohort.
No significant  differences  were  observed  regarding  the  predictive  ability  of  each  of  the  scores
in patients  with  and  without  anemia  (CRUSADE:  AUC  0.73  without  anemia  vs.  0.74  with  anemia,
p=0.913; ACTION:  AUC  0.68  without  anemia  vs.  0.73  with  anemia,  p=0.353;  Mehran:  AUC  0.69
without anemia  vs.  0.61  with  anemia,  p=0.210).  Only  the  Mehran  score  showed  significantly
lower predictive  ability  in  patients  with  hemoglobin  <11 g/dl (AUC  0.51,  p=0.044).
Conclusions:  Anemia  was  a  common  comorbidity  in  patients  with  ACS  from  our series.  Cur-
rently available  bleeding  risk  scores  showed  an  adequate  predictive  ability  in patients  with
mild  anemia.
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PALAVRAS-CHAVE






Em doentes  com  síndromes  coronárias  agudas,  a presença  de anemia  altera
a  capacidade  preditiva  de  scores  de  risco  hemorrágico?
Resumo
Introdução  e  objetivo:  A anemia  é uma comorbilidade  frequente  em  doentes  com  síndromes
coronárias agudas  (SCA)  e associa-se  tanto  a  um  maior  risco  de  hemorragia,  como  de
complicações isquémicas.  O  nosso  objetivo  foi  avaliar  a  capacidade  preditiva  de scores  de  risco
de hemorragia  (Can  Rapid  risk  stratification  of  Unstable  angina  patients  Suppress  ADverse
outcomes with  Early  implementation  of the  ACC/AHA  guidelines  [CRUSADE],  Mehran  e  Acute
Coronary Treatment  and  Intervention  Outcomes  Network  [ACTION])  em  doentes  com  SCA
e anemia.
Métodos:  Todos  os doentes  consecutivos  com  SCA  foram  prospetivamente  incluídos.  O  resul-
tado primário  foi  a  hemorragia  intra-hospitalar  major,  de acordo  com  as  definições  CRUSADE,
Mehran e  ACTION.  A anemia  foi definida  como  uma  concentração  de  hemoglobina  <130  g/L  em
homens e <120  g/L  em  mulheres.  A capacidade  preditiva  dos  scores  de risco  de  hemorragia
foi avaliada  pelo  método  de  regressão  logística  binária,  calculando  curvas  ROC  e a  sua  área
correspondente  sob  a  curva  (AUC).
Resultados:  Foram  incluídos  2255  doentes.  A  média  de idades  foi de 62,4  anos.  A  anemia  estava
presente  em  550  doentes  (24,4%).  Doentes  com  anemia  apresentaram  uma  prevalência  significa-
tivamente maior  de  comorbilidades.  Os  três  scores  de risco  previram  corretamente  hemorragia
major  no conjunto  da  coorte.
Não  se  observaram  diferenças  significativas  em  relação à  capacidade  preditiva  de  cada  um  dos
scores de  risco  de hemorragia  em  pacientes  com  e sem  anemia  (CRUSADE  AUC  0,73  sem  anemia
versus 0,74  com  anemia;  p<0,913;  ACTION  AUC  0,68  sem  anemia  versus  0,73  com  anemia;
p<0,353; Mehran  AUC  0,69  sem  anemia  versus  0,61  com  anemia  p<0,210).  Apenas  o score  Mehran
mostrou uma  capacidade  preditiva  significativamente  menor  nos  doentes  com  hemoglobina
<11 g/dL  (AUC  0,51,  p<0,044).
Conclusões:  Na nossa  amostra,  a  anemia  foi  uma comorbilidade  frequente  em  doentes  com  SCA.
Os scores  de  risco  de  hemorragia  estudados  mostraram  uma capacidade  de  previsão  adequada
em doentes  com  anemia  leve.
© 2016  Sociedade  Portuguesa  de  Cardiologia.  Publicado  por  Elsevier  España,  S.L.U.  Todos  os
direitos reservados.
Introduction
The  incidence  of  major  bleeding  in patients  with  acute  coro-
nary  syndromes  (ACS)  ranges  from  3  to  5%.1--5 Major  bleeding
events  are  associated  with  worse  outcomes  in  this clinical
setting.6--8 Several  bleeding  risk  scores9--11 have  been  devel-
oped  in  recent  years  in order  to  properly  predict  bleeding
complications  in patients  with  ACS,  and their  use  is  rec-
ommended  in the current  clinical  guidelines.12 However,  it
has  been  suggested  that  these  scores  have  lower  predictive
ability  in  the elderly13 and  in patients  with  comorbidi-
ties.
Anemia  is  a  common  comorbidity  among  patients  with
ACS,14 and its  prevalence  is expected  to  increase  due  to the
aging  of  the  population.  Anemia  is  associated  with  higher
risk  for  both  bleeding  and  ischemic  complications  in patients
with  ACS.15 Information  on  the predictive  ability  of  bleeding
risk  scores  in  patients  with  anemia  is  scarce;  no  study  has
assessed  the  performance  of  bleeding  risk  scores  according
to  hematocrit  status in  patients  with  ACS.  The  aim  of  this
study  was  to  assess  the predictive  ability  of  the most widely
used  bleeding  risk  scores  according  to  anemia  status  in  a
series  of consecutive  patients  with  ACS  from  routine  clinical
practice.
Methods
Study  design  and  population
This is  an observational  single-center  registry,  conducted
at a  tertiary  care  hospital  in Spain  (Hospital  Universitari
de  Bellvitge,  l’Hospitalet  de Llobregat,  Barcelona).  All  con-
secutive  ACS  patients  admitted  to  the coronary  care  unit
between  October  2009  and April  2014  were  prospectively
included.  Informed  consent  was  provided  by  all  patients
before  their  inclusion  in  the  study. Confidential  patient  data
were  protected  according  to current  national  directives.
This  manuscript  was  revised  for publication  by  the Clinical
Research  Ethics  Committee  of  Bellvitge  University  Hospital
(IRB00005523).
The primary  outcome  was  in-hospital  major  bleeding
according  to  the CRUSADE,9 Mehran10 and  ACTION11 defini-
tions.
Definitions,  data  collection  and management
Non-ST-segment  elevation  ACS  was  defined  as  the  presence
of  chest  pain  during  the previous  48  hours  with  ST-segment
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Table  1  Baseline  and  clinical  characteristics  according  to  hematocrit  status.
Whole  cohort  (n=2255)  Anemia  (n=550)  No anemia  (n=1705)  p
Male  1727  (76.6)  372 (67.6)  1355  (795)  0.001
Age 62.4  (13)  68.9  (12)  60.3  (13)  0.001
BMI (kg/m2) 27.9  (4) 27.8  (5) 27.9  (4)  0.532
BSA (m2) 1.9  (0.2) 1.8  (0.2) 1.9  (0.2)  0.001
Diabetes 674 (29.9) 260  (47.3) 414  (24.3) 0.001
Hypertension  1335  (59.2) 407  (74) 928  (54.4) 0.001
Dyslipidemia  1302  (57.7)  350 (63.6)  952  (55.8)  0.001
Active smoking  947 (42.7)  127 (23.4)  820  (48.9)  0.001
Previous MI  315 (14)  126 (22.9)  189  (11.1)  0.001
Previous PCI  264 (11.7)  123 (22.4)  141  (8.3)  0.001
Previous stroke  157 (6.9)  73  (13.3)  84  (4.9)  0.001
PAD 256  (11.4)  121 (22)  135  (7.9)  0.001
Hematocrit (%) 41  (5) 34  (4) 43  (4)  0.001
Creatinine clearance  (ml/min)  91.7  (40)  70.4  (36)  98.5  (39)  0.001
Previous bleeding  78  (3.5)  37  (6.7)  41  (2.4)  0.001
STEMI 1461  (64.8)  304 (55.3)  1157  (67.9)  0.001
Killip class  >I  441 (19.6)  173 (31.5)  268  (15.7)  0.001
SBP (mmHg)  130 (34)  129 (28)  130  (36)  0.476
HR (bpm)  80  (17)  81  (18)  79  (17)  0.090
LVEF (%)  51.9  (11)  49.9  (11)  52.5  (11)  0.001
CRUSADE score  26  (16)  39  (17)  22  (14)  0.001
Mehran score  17  (8) 24  (7) 14  (7)  0.001
ACTION score  30  (8) 35  (7) 28  (7)  0.001
GRACE score  124 (36)  138 (37)  118  (34)  0.001
Invasive strategy  2170  (96.2)  516 (93.8)  1654  (97)  0.001
Radial approach  1455  (67.1)  296 (57.4)  1159  (70.1)  0.001
BMI: body mass index; BSA: body surface area; HR: heart rate; LVEF: left ventricular ejection fraction; MI: myocardial infarction;
PAD: peripheral arterial disease; PCI: percutaneous coronary intervention; SBP: systolic blood pressure; STEMI: ST-segment elevation
myocardial infarction.
Categorical variables are expressed as n  (%). Quantitative variables are expressed as mean (SD).
changes  on the electrocardiogram  indicating  ischemia  or
a  positive  troponin  test.  ST-segment  elevation  ACS  was
defined  as  the  presence  of  chest  pain  with  persistent  ST-
segment  elevation  of  at least  0.1  mV  in at least  two
contiguous  leads  or  new  left bundle  branch  block.  Patients
were  classified  as  having  anemia  using the definition  of  the
World  Health  Organization  (WHO):  hemoglobin  <13.0  g/dl  in
men,  and  <12.0  g/dl  in women.16 Severe  anemia  was  defined
as  hemoglobin  <11.0  g/dl  for  the purpose  of  this  study.
Data  were prospectively  collected  on  site  by trained
physicians  using  a standardized  case  report  form.  Baseline
characteristics,  medical  history,  biochemical  and  elec-
trocardiographic  findings,  treatments  administered  during
hospitalization,  incidence  of  in-hospital  bleeding  events
and  their  anatomic  location  were  collected.  All elements
included  in  the  CRUSADE,9 Mehran10 and ACTION11 bleed-
ing  risk  scores  were  included  in the  case  report  forms.  The
development  of  these  scores  has  been  described  in  detail
previously.  The  CRUSADE,  Mehran  and  ACTION  bleeding  risk
scores  were  all  prospectively  calculated  for each  patient.
In-hospital  major  bleeding  events  were  recorded  using
the  CRUSADE,9 TIMI,12 Mehran,10 ACTION11 and Bleeding  Aca-
demic  Research  Consortium  (BARC)17 definitions.  For  reasons
of  clinical  relevance,  BARC  categories  3 and  5  were  consid-
ered  severe  BARC  bleeding  for  this  study.  Since  the main  aim
of the  present  analysis  was  to  identify  the risk  of  bleeding
unrelated  to  surgery,  bleeding  in patients  who  underwent
coronary  artery bypass  graft  surgery  was  included  in the
analysis  only  if it occurred  before  surgery.  Thus,  BARC  cat-
egory 4  was  excluded.
All elements  included  in the BARC  category  2  crite-
ria  (need for  nonsurgical  medical  intervention,  need  for
increased  level  of  care,  prompting  evaluation,  baseline
and  lowest  recorded  hemoglobin,  need  for  transfusion  or
surgery,  requirement  for  intravenous  vasoactive  drugs)  were
included  in the  case  report  form,  the data  thus  being
prospectively  collected.  However,  since  the  BARC  definition
was  not  available  until  2011,  BARC  bleeding  events  were  ret-
rospectively  assigned.  ACTION,  CRUSADE  and Mehran  major
bleeding  events  were  prospectively  adjudicated.
The  quality  of  data  collection  was  assessed  by  check-
ing  source  documentation  in random  samples.  Hemodynamic
parameters  (heart  rate  and  systolic  blood  pressure)  and  Kil-
lip  class  were  measured  at  admission.  Creatinine  clearance
was  calculated  using  the  Cockcroft-Gault  formula18 and body
surface  area by  the Mosteller  formula.19 Patients  were  man-
aged  according  to  current  clinical  guidelines.
Information  on deaths  was  obtained  from  hospital
records,  death  certificates,  or  telephone  contact  with  rela-
tives  of the  patients  or  their  referring  physician.
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Statistical  analysis
Quantitative  variables  were  expressed  as  mean  and  standard
deviation.  For  baseline  variables,  the  Student’s  t  test  was
used  for  comparison  of  quantitative  variables  and  the chi-
square  test  or  Fisher’s  exact  test,  when  appropriate,  were
used  for  categorical  variables  (PASW Statistics  18, Chicago,
IL,  USA).  The  normality  of  distribution  of  variables  was
assessed  using  the  Kolmogorov-Smirnov  test.
Patients  with  missing  hemoglobin  values  and  those  lost  to
follow-up  were  excluded  from  the analysis.  Baseline  patient
characteristics  were  analyzed  in  order  to  assess  the  impact
of  this  exclusion.  No  significant  differences  were  observed.
The  ability  of  the CRUSADE,  Mehran  and ACTION  bleeding
risk  scores  to  predict  major  in-hospital  bleeding  according  to
different  definitions  was  assessed  by  binary  logistic  regres-
sion,  calculating  receiver  operating  characteristic  (ROC)
curves  and  their  corresponding  area  under  the curve  (AUC).
The  non-parametric  method  described  by  DeLong20 was  used
to  compare  the predictive  ability  of  the  different  bleeding
risk  scores.
Results
During  the  study  period  2255  patients  were  admitted  with  a
diagnosis  of ACS.  Their  mean  age  was  62.4  years,  and almost
77%  were  male.  Anemia  was  present  in 550  patients  (24.4%).
Patients  with  anemia  were  significantly  older,  less  often
male  and had  a significantly  higher  prevalence  of comor-
bidities  (Table  1).
Patients  with  anemia  also  had  poorer  renal  function
at  admission,  a lower  incidence  of  ST-segment  elevation
myocardial  infarction  and  a higher  percentage  of  signs of
heart  failure  at presentation.  Values  of  CRUSADE,  Mehran
and  ACTION  bleeding  risk  scores  were  all  significantly  higher
in  patients  with  anemia.
Significant  differences  were  also  observed  regarding  clin-
ical  management  (Table 2). Patients  with  anemia  were
less  often  treated  with  clopidogrel  and  abciximab,  and
more  often  needed  invasive  procedures  during hospitaliza-
tion,  such  as  intra-aortic  balloon  counterpulsation,  renal
replacement  therapy,  invasive  mechanical  ventilation  and
temporary  pacing.  Patients  with  anemia  less  often  under-
went  an  invasive  strategy,  and  in patients  undergoing
angiography  a radial  approach  was  used less  often  than  in
patients  without  anemia.
These  patients  had  also  a  higher  incidence  of  in-hospital
complications  such  as  atrial  fibrillation,  atrioventricu-
lar  block,  contrast-induced  nephropathy  and infectious
complications  requiring  antibiotics.  Bleeding  was  signifi-
cantly  more  common  in patients  with  anemia  regardless  of
the  definition  used.  In-hospital  mortality  was  almost  three
times  higher  in patients  with  anemia.
Bleeding risk  prediction  according to anemia
status
The  three  bleeding  risk  scores  adequately  predicted  major
bleeding  according  to  their  own  definitions  in the  whole
cohort  (Figure  1). No significant  differences  were observed
regarding  the  predictive  ability  of  the bleeding  risk  scores
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Figure  1  Receiver  operating  characteristic  curves  of  each  of
the bleeding  risk  scores  for  predicting  major  bleeding  in the
whole  cohort.  AUC:  area  under  the  curve.
in patients  with  and  without  anemia.  While the  predictive
ability  of  the  CRUSADE  score  was  almost  the same  as  for
the whole  cohort,  the  AUC  of the ACTION  score  was  slightly
greater  and  that  of  the Mehran  score  was  slightly  smaller,
without  reaching  statistical  significance.  Figure  2 shows  the
AUCs  of  each  of  the three  bleeding  risk  scores  in patients
with  and  without  anemia.
The  assessment  of  patients  with  severe  anemia  showed
different  findings.  The  predictive  ability  of  both  the CRU-
SADE  and  ACTION  scores  decreased  slightly  in patients  with
severe  anemia,  but  without  significant  difference.  In  con-
trast,  the predictive  ability  of  the Mehran  score showed  a
significant  decrease  in patients  with  severe  anemia.  Table  3
shows  the AUC  values  of  each  of  the bleeding  risk  scores  in
patients  without  anemia,  with  anemia  according  to  the  WHO
criteria,  and  with  severe  anemia.
Discussion
The  main  findings  from  our  study  are:  (a)  a high  preva-
lence  of  anemia  was  found  in a series  of unselected  ACS
patients  from  routine  clinical  practice;  (b)  no  significant
differences  were observed  regarding  the predictive  ability
of  the  three  bleeding  risk  scores  in  patients  with  or  with-
out  anemia  according  to  the  WHO  criteria;  and  (c)  only  the
Mehran  risk  score  showed  a  significantly  poorer  predictive
ability  in  patients  with  severe  anemia.
Anemia  is  a common  comorbidity  in ACS,  and  is  strongly
associated  with  higher  mortality  and  morbidity  in this
setting.15,21,22 The  reasons  for this association  have  not  been
clearly  elucidated.  Anemia  worsens  myocardial  ischemia  by
reducing  oxygen  delivery  to  the injured  myocardium  as  well
as  by  increasing  myocardial  oxygen  demands  due  to  a larger
stroke  volume  and  higher  heart  rate.  At  the same  time,
anemia  potentially  reflects  occult  disease,  such  as  malig-
nancy  or  kidney  disease,  and  can have  unfavorable  effects
on  the  clinical  course  of  noncardiac  disease.  Recent  data
suggest  that  causes  of  mortality  in patients  with  ACS  and
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Table  2  Management  and  clinical  course  according  to  hematocrit  status.
Whole  cohort  (n=2255)  Anemia  (n=550)  No  anemia  (n=1705)  p
Anti-thrombotic  treatments  and  in-hospital  procedures
Aspirin 2186  (97.2)  525  (96)  1661  (97.5)  0.057
Clopidogrel  2083  (92.6) 489  (89.4) 1594  (93.6) 0.001
Prasugrel  36  (1.2)  11  (2)  25  (1.5)  0.379
Ticagrelor 73  (3.2)  11  (2)  62  (3.6)  0.061
Enoxaparin  1020  (45.3)  259  (47.3)  761  (44.7)  0.276
UFH 1168  (51.9)  261  (47.7)  907  (53.3)  0.024
Bivalirudin  236  (10.5)  49  (9)  187  (11)  0.179
Abciximab  328  (14.6)  47  (8.6)  281  (16.5)  0.001
IABP 156  (6.9)  68  (12.4)  88  (5.2)  0.001
Swan-Ganz catheter 54  (2.5) 22  (4.2) 32  (2)  0.005
Hemodialysis  29  (1.3)  25  (4.5)  4 (0.2)  0.001
Invasive mechanical  ventilation  124  (5.5)  40  (7.3)  84  (4.9)  0.036
Temporary  pacemaker  69  (3.1)  28  (5.1)  41  (2.4)  0.001
In-hospital clinical  course
AV  block 156  (7)  54  (10.1)  102  (6.1)  0.002
Atrial fibrillation  158  (7)  63  (11.5)  95  (5.6)  0.001
Ventricular fibrillation 138  (6.4)  32  (6.2)  106  (6.5)  0.769
Reinfarction 17  (0.8) 6  (1.1)  11  (0.6)  0.216
VSD 5  (0.2)  -  5 (0.3)  0.247
CIN 98  (4.3) 48  (8.7)  50  (2.9)  0.001
Ischemic MR 10  (0.4) 6  (1.1) 4  (0.2)  0.009
Cardiac rupture 14  (0.7) 4  (0.7)  10  (0.6)  0.267
Infections  120  (5.3) 57  (10.4) 63  (3.7)  0.001
All bleeding 164  (7.3) 55  (10) 109  (6.4) 0.005
Transfusion 64  (2.8) 44  (6) 20  (1.2)  0.001
CRUSADE major  bleeding 115  (5.1) 39  (7.1) 76  (4.5) 0.015
Mehran major  bleeding  136  (6)  49  (8.9)  87  (5.1)  0.001
ACTION major  bleeding  116  (5.1)  40  (7.3)  76  (4.5)  0.009
BARC 3/5  bleeding  61  (2.7)  24  (4.4)  37  (2.2)  0.006
In-hospital  mortality  90  (4.1)  43  (8)  47  (2.8)  0.001
AV: atrioventricular block; BARC: Bleeding Academic Research Consortium; CIN: contrast-induced nephropathy; IABP: intra-aortic bal-
loon pump; MR: mitral regurgitation; UF: unfractionated heparin; VSD: ventricular septal defect. Infections were defined as infectious
complications requiring antibiotics.
Categorical variables are expressed as n  (%). Quantitative variables are expressed as mean (SD).
anemia  may  differ according  to  age subgroups.23 As  reported
above,  patients  with  anemia  from  our  series  were  signifi-
cantly  older,  with  a  higher  incidence  of  comorbidities  and
higher  in-hospital  mortality.
In  addition,  anemia  is  a well-known  predictor  of
bleeding24 in  patients  with  ACS.  However,  although  currently
available  bleeding  risk  scores  have  been  successfully  val-
idated  in  different  subsets,25--27 there  is  little  information
on bleeding  risk  stratification  in patients  with  anemia.  Our
group  previously  described13 a  poorer  performance  of  the
three  bleeding  risk  scores  in  predicting  major  in-hospital
bleeding  in patients  with  ACS  aged  75  years  or  older.  One
possible  explanation  for these  findings  is  that  certain  aging-
related  variables  such as  frailty,  disability,  or  comorbidities,
which are rarely  assessed  in trials  and  registries  in the car-
diovascular  area,  might  hamper  bleeding  risk  stratification




AUC  (95%  CI)
(n=1705)
Anemia  by  WHO
criteria,  AUC  (95%
CI)  (n=550)
Severe  anemia,a
AUC  (95%  CI)
(n=173)
No  anemia  vs.
anemia  by  WHO
criteria,  p
No  anemia  vs.
severe
anemia,a p
CRUSADE  0.73  (0.67-0.80)  0.74  (0.65-0.83)  0.62  (0.49-0.76)  0.913  0.552
Mehran 0.69  (0.63-0.75)  0.61  (0.51-0.71)  0.51  (0.38-0.65)  0.210  0.044
ACTION 0.68  (0.60-0.75)  0.73  (0.64-0.82)  0.61  (0.50-0.72)  0.353  0.181
AUC: area under the curve; CI:  confidence interval; WHO: World  Health Organization.
a Hemoglobin <11 g/dl.
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AUC Mehran (no anemia): 0.69,95% CI 0.63-0.7 5
AUC Mehran (anemia): 0.61,95% CI 0.51-0.7 1
AUC Action (no anemia): 0.68,95% CI 0.60-0.75
 AUC Action (anemia): 0.73,95% CI 0.64-0.82
AUC Crusade (no anemia): 0.73,95% CI 0.67-0.8
AUC Crusade (anemia): 0.74,95% CI 0.65-0.83
Figure  2  Receiver  operating  characteristic  curves  of  each  of the bleeding  risk  scores  for  predicting  major  bleeding  in  patients
with and  without  anemia  according  to  the World  Health  Organization  criteria.  AUC:  area  under  the  curve.
in  this  clinical  scenario.  In  addition,  most  registries  show  a
strong  association  between  anemia  and other  comorbidities
in  different  clinical  settings.  In  the  previously  mentioned
paper,13 elderly  patients  with  ACS  had a significantly  higher
prevalence  of  anemia  compared  to younger  patients.  There-
fore,  poorer  predictive  ability  could  also  be  expected  in
patients  with  anemia.  However,  data  from  our  series  showed
no  significant  differences  regarding  the  predictive  ability  of
the  bleeding  risk  scores  in patients  with  and  without  anemia.
An  important  point when  analyzing  our  findings  is  the
role  of  hematocrit  status  in the composition  of  the  dif-
ferent  bleeding  risk  scores.  Hemoglobin  level  is  part  of
the  CRUSADE,9 Mehran10 and  ACTION11 risk  scores,  but  the
contribution  of hemoglobin  values  to these scores  varies.
While  in  CRUSADE  and Mehran  hemoglobin  levels  account
for  around  10%  of  the  overall  points,  in ACTION  they  repre-
sent  almost  20%  of  the  score.  Assessment  of the  predictive
ability  of  these bleeding  risk  scores  stratified  by one of their
components  might  in  itself  lead  to  a  reduction  in the AUC.
In  our  opinion,  the  non-significant  reduction  in AUC  values
in patients  with  anemia  may  at least  in  part be due  to  this
fact,  especially  for  the ACTION  score,  given  the greater
role  of  hemoglobin  status  in the  overall  composition  of  the
score.
The  differences  in  therapeutic  management  according
to  anemia  status  in our  series  also  deserves  particular
mention.  Patients  with  anemia  underwent  more  conser-
vative  antithrombotic  management,  thus  possibly  leading
to  a  reduction  in the  rate  of  bleeding  and  potentially
affecting  the performance  of  bleeding  risk  scores.  How-
ever,  this  management  was  performed  according  to  current
recommendations,  since  patients  with  anemia  are  usually
considered  at higher  bleeding  risk  and  a more  conserva-
tive  antithrombotic  approach  is  encouraged  in  this  scenario.
In our  opinion, one  of  the strengths  of  this  work  is its
assessment  of  the  performance  of  the current  bleeding  risk
scores  in  patients  from our routine  clinical  practice  man-
aged  according  to  the clinical  judgment  of  the attending
physician,  taking  into  account current  recommendations  and
patients’  profile  in terms  of ischemic  and  bleeding  risk.
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The  different  characteristics  of the populations  from
whom  these  scores  were derived  also  deserve  special
comment.  The  CRUSADE  and  ACTION  scores  were  based
on  large  American  registries  (89  134  patients  for  CRU-
SADE  and  90  273 for  ACTION)  with  baseline  characteristics
that  were  probably  similar  to  patients  included  in our
study.  In  contrast,  the  Mehran  score  was  based  on  17  421
patients  included  in  two  clinical  trials  (ACUITY  and  HORI-
ZONS  AMI).  Populations  from  clinical  trials  usually  have
a  low  prevalence  of  comorbidities  and  patients  at higher
risk  are  usually  under-represented.  The  prevalence  of ane-
mia  in  Mehran  et  al.’s  series  was  clearly  lower  (14.5%)
than  in  ours.  The  poorer  predictive  ability  of  the Mehran
score  in patients  with  severe  anemia  may  be  related
to  this  fact.  However,  these  data  must  be  interpreted
cautiously  due  to  the  small  sample  size  of  this  sub-
group.
Our  study  has  several  limitations.  This  is  a single-center
study  and  therefore  our conclusions  should  be  applied  only
to  similar  populations  undergoing  similar  clinical  mana-
gement.  Since  this is  an  observational  study  we  cannot
rule  out  the  possibility  of  selection  bias  and  residual
confounding.  The  cutoff  point  of  <11.0  g/dl  for  defining
severe  anemia  was  selected  by  investigators  after  assessing
the  distribution  of hemoglobin  in our  series.  The  num-
ber  of  bleeding  events  was  relatively  small.  In addition,
the  use  of  novel  antithrombotic  drugs  like prasugrel  or
ticagrelor  was  uncommon.  On  the  other  hand,  excluding
patients  with  missing  bleeding  scores  might  have  led to a
certain  bias.  However,  analysis  of  the baseline  character-
istics  of these  patients  showed  no  significant  differences
from  the  other  patients.  Finally,  the Mehran  bleeding  risk
score  was  designed  to  predict  bleeding  during the first
30  days  and  not only  during  hospitalization  as  in our
study.
In  spite  of  these  limitations,  we  believe  that our  find-
ings  show  reasonably  acceptable  predictive  ability  in the
main  available  bleeding  risk  scores  in a series  of  consecutive
ACS  patients  with  and  without  anemia  from  routine  clinical
practice.
Conclusions
The prevalence  of  anemia  was  high  in our  series  of  unselec-
ted  ACS  patients  from routine clinical  practice.  The  ability
of  the  most  important  currently  available  bleeding  risk
scores  to predict  in-hospital  major  bleeding  was  accept-
able  in  patients  with  anemia,  especially  in patients  with
mild  anemia.  The  progressive  aging  of  the  population  makes
it  particularly  important  to  improve  risk  stratification  in
patients  with  comorbidities.
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